| Pharmaceutical Information |
| Drug Name |
Auranofin |
| Drug ID |
BADD_D00191 |
| Description |
Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. |
| Indications and Usage |
Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis. |
| Marketing Status |
approved; investigational |
| ATC Code |
M01CB03 |
| DrugBank ID |
DB00995
|
| KEGG ID |
D00237
|
| MeSH ID |
D001310
|
| PubChem ID |
24199313
|
| TTD Drug ID |
D0L2UN
|
| NDC Product Code |
54766-093; 49812-0067 |
| UNII |
3H04W2810V
|
| Synonyms |
Auranofin | Ridaura | SK&F D 39162 | SK&F-39162 | SK&F 39162 | SK&F39162 | Crisinor | Ridauran |
|
| Chemical Information |
| Molecular Formula |
C20H34AuO9PS |
| CAS Registry Number |
34031-32-8 |
| SMILES |
CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
